Natacha Bolaños, Lymphoma Coalition, Madrid, Spain, discusses the accessibility of CAR T-cell therapy as well as the variability on the eligibility criteria across different counties in Europe and how it can relate to patients’ outcomes. Ms Bolaños is particularly interested in understanding how real world data may help the selection of patients who will benefit from CAR T-cell therapy. This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.